Stephane Bardet
Expertise in
9
conditions

Stephane Bardet

Caen, FR 
Expertise in
9
conditions
Caen, FR 
OverviewLocationsClinical Research

Overview

Stephane Bardet practices in Caen, France. Ms. Bardet is highly rated in 9 conditions, according to our data. Her top areas of expertise are Thyroid Cancer, Parathyroid Adenoma, Parathyroid Cancer, Anaplastic Thyroid Cancer, and Thyroidectomy.

Her clinical research consists of co-authoring 72 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Caen, France
Other Locations
Groupement Hospitalier Est, Les Abimes, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
Enrollment Status: Completed
Publish Date: August 16, 2019
Intervention Type: Drug
Study Phase: Phase 2
Diagnostic Value of 18F-Choline PET/CT in Patients With a Thyroid Nodule With an Indeterminate Cytology: Pilot Study
Diagnostic Value of 18F-Choline PET/CT in Patients With a Thyroid Nodule With an Indeterminate Cytology: Pilot Study
Enrollment Status: Completed
Publish Date: March 29, 2019
Intervention Type: Device
Study Phase: Not Applicable
Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas
Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas
Enrollment Status: Completed
Publish Date: January 04, 2018
Intervention Type: Radiation
Study Phase: Phase 2
View 3 Less Clinical Trials

72 Total Publications

ENDOCAN TUTHYREF network consensus recommendations: ANAPLASTIC THYROID CANCER.
ENDOCAN TUTHYREF network consensus recommendations: ANAPLASTIC THYROID CANCER.
Journal: Annales d'endocrinologie
Published: April 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Bardet's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 17 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile